Keros Therapeutics, Inc. (KROS) — Total Liabilities
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $34.89M | -21.3% |
| 2024 | $44.33M | +17.2% |
| 2023 | $37.81M | +28.8% |
| 2022 | $29.36M | +143.1% |
| 2021 | $12.08M | +56.4% |
| 2020 | $7.72M | -26.2% |
| 2019 | $10.46M | — |
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $34.89M | -21.3% |
| 2024 | $44.33M | +17.2% |
| 2023 | $37.81M | +28.8% |
| 2022 | $29.36M | +143.1% |
| 2021 | $12.08M | +56.4% |
| 2020 | $7.72M | -26.2% |
| 2019 | $10.46M | — |